Browse the evidence

The most common components of metabolic syndrome in the cohort were abdominal obesity and elevated blood pressure.

Understanding common MetS components can guide targeted interventions.

Low energy availability did not enhance performance when expressed relative to body mass.

Performance assessments should consider body mass to accurately evaluate the effects of energy availability.

In the intervention group, there was statistically significantly higher Part B spending compared to the control group (difference, $513; P = .02).

Practitioners should be aware that while overall spending did not decrease, specific areas like Part B spending increased.

No evidence of a relationship was found between RIR accuracy and biological sex, years of RT experience, or relative bench press strength.

RIR accuracy can be considered independent of these demographic and experiential factors.

GLP-1 receptor agonists were originally developed as glucose lowering agents.

Understanding the original purpose of GLP-1 receptor agonists can inform their use in weight management.

The incidence of obesity-related glomerulopathy has increased 10-fold in recent years.

Awareness of obesity-related kidney issues is essential for healthcare providers.

Indirect calorimetry is the favored method to assess human energy expenditure and is the only method enabling the assessment of macronutrient oxidation.

Practitioners should consider using indirect calorimetry for accurate assessment of energy expenditure and macronutrient oxidation.

The doubly labeled water method provides accurate assessment of human energy expenditure under free living conditions.

Practitioners can use the doubly labeled water method for accurate energy expenditure assessments in free living individuals.

There is a lack of evidence on the efficacy of various methodologies used by physique competitors to improve body composition.

Practitioners should be cautious about methodologies lacking evidence.

Semaglutide may improve wait-list times for renal transplantation by overcoming obesity as a barrier.

Addressing obesity in patients may facilitate their eligibility for renal transplantation.

Gender, household size, and education were associated with GLP-1 use and interest.

Marketers should consider demographic factors when targeting potential GLP-1 consumers.

The use of medications for obesity will likely require lifelong treatment.

Practitioners should prepare for long-term management strategies when prescribing obesity medications.

Persistence in the OMM-eligible cohort was 73.8%.

High persistence rates suggest good adherence to tirzepatide among eligible patients.

Real-world evidence suggests slower tirzepatide dose escalation than in clinical trials.

Practitioners may need to adjust expectations regarding dose escalation in real-world settings.

DTC genetic tests are marketed with faux scientific authority, potentially confusing consumers.

Practitioners should help consumers navigate the complexities of DTC genetic test marketing.

Obesity is projected to affect approximately half the US population by the year 2035.

Practitioners should be aware of the increasing prevalence of obesity for public health planning.

The question of ideal macronutrient composition for metabolic syndrome is difficult to address and control in clinical practice.

Recognize the complexities involved in dietary recommendations for metabolic syndrome.

Human body weight is physiologically regulated and maintained within a relatively narrow range in most mammals, including humans.

Understanding body weight regulation can inform strategies for managing obesity.

Difficulties in achieving body weight loss and maintenance in obese subjects are partly due to physiological regulatory systems that resist weight loss.

Recognizing these physiological challenges can guide effective weight loss strategies.

Restricting dietary carbohydrates does not offer a metabolic advantage for burning more calories to maintain lost weight.

Diet composition may not significantly impact energy expenditure for weight maintenance.

Obesity is a global epidemic and a significant public health challenge.

Recognize obesity as a critical issue in public health.

Current anti-obesity medications (AOMs) include gastrointestinal lipase inhibitors, nutrient-stimulated hormone-based therapies, and emerging multi-receptor agonists.

Consider these AOMs in obesity treatment strategies.

The prevalence of obesity among youth with type 1 diabetes increased from 18.1% to 26.0% from 2008-2011 to 2020-2023.

Healthcare providers should be aware of the rising obesity rates in youth with T1D for better management strategies.

The prevalence of obesity among adults with type 1 diabetes rose from 30.5% to 38.1% from 2008-2011 to 2020-2023.

Healthcare providers should recognize the increasing obesity rates in adults with T1D for effective treatment planning.